This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
In 2019, 8 874 (7.4%) of patients staying in an intensive care unit (ICU) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection, or urinary tract infection).
Between 2018 and 2020, nearly 20 000 surgical site infections (SSIs) were reported from a total of over 1.2 million surgical procedures in 13 EU/EEA countries participating in ECDC-coordinated SSI surveillance. Over 2 500 hospitals are part of this surveillance network.
In 2018, 9 860 (7.8%) of patients staying in an intensive care unit (ICU) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection or urinary tract infection).
The 2016–2017 ECDC point prevalence survey was the second EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This report is based on data for 2018-2020 retrieved on 13 February 2023 from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI). TESSy is a system for the collection, analysis and dissemination of data on communicable diseases.